Intercell AG, the Austrian vaccine developer, made a restructuring and impairment charge in the 2010 fourth quarter of €182.8 million, mainly as the result of terminating a vaccine patch project in Phase 3 development. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
